IP Library Patent Application 10564031
Patent Application
App. No. 10/564,031

Intravaginal drug delivery devices

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/564,031
Abstract

The invention relates to an intravaginal drug delivery device comprising at least one reservoir, the, or each, reservoir containing at least one pharmacologically active agent dispersed in a carrier system; and a sheath discontinuously surrounding the at least one reservoir, so that, in use, at least part of that reservoir is directly exposed to the vaginal environment. Preferably, the sheath defines one or more holes or openings, the, or each, hole or opening extending through the sheath to the at least one reservoir, so that at least part of that reservoir is exposed, in use, to the vaginal environment.

Claims (18)

1 . An intravaginal drug delivery device for administration into a vaginal environment, the device comprising at least one reservoir, the, or each, reservoir containing at least one pharmacologically active agent or a prodrug thereof, dispersed in a carrier system; and a sheath discontinuously surrounding the at least one reservoir, so that, in use, at least part of the at least one reservoir is directly exposed to the vaginal environment.

2 . An intravaginal drug delivery device according to claim 1 , in which the sheath defines one or more holes or openings, the, or each, hole or opening extending through the sheath to the at least one reservoir, so that at least part of the it least one reservoir is exposed, in use, to the vaginal environment.

3 . An intravaginal drug delivery device according to claim 2 , in which the, or each, hole or opening extends to the surface of the at least one reservoir and/or extends partially into the at least one reservoir.

4 . An intravaginal drug delivery device according to claim 2 , in which the, or each, hole or opening is of any shape or is joined with an adjacent hole or opening to give a continuous opening in the form of a slit.

5 . An intravaginal drug delivery device according to claim 2 , in which the, or each, hole or opening is substantially cylindrical with a diameter in the range of about 0.5 to 6.5 mm.

6 . An intravaginal drug delivery device according to claim 2 , in which the, or each, hole or opening extends through the sheath substantially normal to the reservoir surface.

7 . An intravaginal drug delivery device according to claim 2 , in which the device is substantially circular in transverse cross-section, and the, or each, hole extends substantially radially, inwardly or outwardly, through the sheath.

8 . An intravaginal drug delivery device according to claim 7 , in which there are one to thirty of said holes, optionally aligned linearly, along the inner or outer circumference of the intravaginal drug delivery device.

9 . An intravaginal drug delivery device according to claim 2 , in which the device is a substantially cylindrical rod device, and said holes are provided at each terminal end of the rod.

10 . An intravaginal drug delivery device according to claim 9 , in which the rod device defines a right circular cylinder and each base of the rod is partly or fully exposed, to define said holes.

11 . An intravaginal drug delivery device according to claim 9 , in which further holes or slits are provided extending substantially radially through the sheath.

12 . An intravaginal drug delivery device according to claim 11 , in which there are one to thirty of said further holes, optionally aligned linearly, along the circumference of the rod.

13 . An intravaginal drug delivery device according to claim 1 , in which the device is a partial or complete toroid shape.

14 . An intravaginal drug delivery device according to claim 1 , in which the reservoir additionally comprises at least one pore-forming excipient.

15 . An intravaginal drug delivery device according to claim 14 , in which the pore-forming excipient comprises a water-soluble or water-swellable polysaccharide, a monosaccharide or a disaccharide, a mater-soluble salt; a protein, a nonionic surface active agent; a bile salt; an organic solvent, or a fatty acid ester.

16 . An intravaginal drug delivery device according to claim 1 , in which the sheath additionally comprises at least one pharmacologically active agent.

17 . A method of manufacturing an intravaginal drug delivery device according to claim 1 , said method comprising the steps of dispersing at least one pharmacologically active agent in a pharmaceutically acceptable carrier system; curing the reservoir; and applying a sheath to partly surround the reservoir.

18 . A method of manufacturing an intravaginal drug delivery device according to claim 1 , said method comprising injecting or extruding a reservoir material into a hollow sheath.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 045417/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT (IRELAND) LIMITED
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 039897/0584 →
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT (IRELAND) LIMITED
Reel/Frame 031394/0587 →
CHANGE OF NAME Recorded Jul 13, 2011
From: GALEN (CHEMICALS) LIMITED
To: WARNER CHILCOTT (IRELAND) LIMITED
Reel/Frame 026584/0948 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT (IRELAND) LIMITED
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026065/0215 →
RELEASE - REEL 023519, FRAME 0430 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT (IRELAND) LIMITED (AS SUCCESSOR IN INTEREST TO GALEN CHEMICALS LIMITED); WARNER CHILCOTT PHARMACEUTICALS S.A.R.L. (SUCCESSOR IN INTEREST TO PROCTOR & GAMBLE PHARMACEUTICALS SARL
Reel/Frame 026042/0220 →
SECURITY AGREEMENT Recorded Nov 16, 2009
From: GALEN (CHEMICALS) LIMITED; PROCTER & GAMBLE PHARMACEUTICALS SARL
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023519/0430 →
CHANGE OF NAME Recorded Jun 18, 2009
From: WARNER CHILCOTT COMPANY, INC.
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 022835/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2006
From: MALCOLM, KARL; WOOLFSON, AARON DAVID
To: GALEN (CHEMICALS) LIMITED
Reel/Frame 017975/0795 →